

Program Hebon Congress



14 November 2024

08:30-09:10	<i>Registration and coffee & tea</i>
09:10-09:15	Welcome by Peter Devilee: Chair Hebon Steering Group
09:15-09:25	Rosa de Groot: Hebon Infrastructure: Empowering Research Today and Tomorrow
Session 1	<i>Risk management in women at increased breast/ovarian cancer risk – Chair: Caroline Drukker</i>
09:25-09:45	Laura Saris: Would you surgically remove your breasts, if you knew that you were at high risk of developing breast cancer? Preliminary results OPTIONS survey among <i>BRCA1/2</i> carriers
09:45-10:00	Lisette Jansen: Eligibility for bilateral prophylactic mastectomy: an expert opinion study in the Netherlands
10:00-10:15	Tamar Gootzen: Impact of a personal history of breast cancer on decision-making for ovarian cancer risk-reduction: an explorative analysis in the TUBA-WISP II study
10:15-10:30	Toine Werker: Risk management for breast and ovarian cancer in <i>BRCA</i> mutation carriers; compliance to the recommended guidelines
10:30-11:00	<i>Break</i>

Session 2	<i>Germline pathogenic variants beyond BRCA: descriptives, cancer risk and prognosis – Chair: Lieke Berger</i>
11:00-11:10	Maartje Schreurs: Association between <i>CHEK2</i> c.1100delC status and age at natural menopause
11:10-11:20	Maartje Schreurs: A different view on outcome in <i>CHEK2</i> c.1100delC breast cancer patients compared with non-carrier patients
11:20-11:35	Ane Schei-Andersen: Deep phenotyping of pathology-confirmed benign lesions in <i>PTEN</i> Hamartoma Tumor Syndrome patients
11:35-11:50	Jella-Rike Spijkervet: Age and histotype of ovarian and breast cancer in <i>PALB2</i> , <i>RAD51C</i> and <i>RAD51D</i> germline pathogenic variants carriers
11:50-12:05	Nicoline Hoogerbrugge: Building The Netherlands Genetic Tumour Risk Registry (NESTOR) to accelerate research on hereditary cancer
12:05-13:05	<i>Lunch</i>

Program Hebon Congress



14 November 2024

Session 3

Bridging the gap: risk-based screening for breast cancer in the family and in the population – Chairs: Margreet Ausems and Maartje Hooning

13:05-14:00

Presentation by Christi van Asperen and Mireille Broeders

Session 4

Clinical implications of Risk Reducing Salpingo-Oophorectomy – Chair: Annette Heemskerk-Gerritsen

14:00-14:20

Liz Loehrer: Breast Density Changes after Risk Reducing Salpingo-Oophorectomy in women with a pathogenic germline variant in *BRCA1* or *BRCA2*

14:20-14:35

Iris Stroot: High-grade serous carcinoma after risk-reducing salpingo-oophorectomy in *BRCA1/2* germline pathogenic variant carriers

14:35-14:50

Anniek Stuursma: Long-term prevalence of and risk factors for sarcopenia in women after premenopausal Risk-Reducing Salpingo-Oophorectomy

14:50-15:30

Break

Session 5

Germline and tumor testing in male patients – Chair: Wouter Koole

15:30-15:50

Eveline Bleiker: Men tested for a germline pathogenic variant in *BRCA1/2*: experiences of male participants of HEBON

15:50-16:05

Iris Kloots: Reflex tumour DNA testing in patients with early castration resistant prostate cancer to advise for genotype matched therapy and pre-screen patients for germline testing

Session 6

Tumor first testing in ovarian cancer patients – Chair: Wouter Koole

16:05-16:20

Lieke Lanjouw: Evaluation of *BRCA1/2* testing rates in epithelial ovarian cancer patients: lessons learned from regions Leiden and Groningen

16:20-16:35

Vera Witjes: Nationwide Implementation and Evaluation of the Tumor-First Workflow for Genetic Testing in Ovarian Carcinoma

16:35-16:45

Closing by Peter Devilee: Chair Hebon Steering Group

16:45-17:30

Drinks